Regulation of hyaluronan and versican deposition by growth factors in fibrosarcoma cell lines

Biochimica et Biophysica Acta - General Subjects

Volumn 1780, Issue 2, 2008, Pages 194-202

  Berdiaki, A ^a   Zafiropoulos, A ^a   Fthenou, E ^a   Katonis, P ^b   Tsatsakis, A ^a   Karamanos, N K ^c   Tzanakakis, G N ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

Basic fibroblast growth factor; Fibrosarcoma; Hyaluronan; Hyaluronan synthases; Platelet derived growth factor BB; Transforming growth factor B2; Versican

Indexed keywords

GROWTH FACTOR; HYALURONIC ACID; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA2; VERSICAN;

ARTICLE; BIOSYNTHESIS; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; FIBROSARCOMA; GENE SEQUENCE; HUMAN; HUMAN CELL; LUNG FIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; UPREGULATION;

CELL LINE, TUMOR; FIBROBLAST GROWTH FACTOR 2; FIBROSARCOMA; GLUCURONOSYLTRANSFERASE; HUMANS; HYALURONIC ACID; PLATELET-DERIVED GROWTH FACTOR; PROTEIN ISOFORMS; TRANSFORMING GROWTH FACTOR BETA2; VERSICANS;

EID: 38549176061     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2007.10.005     Document Type: Article

References (63)

1. Timar J., Lapis K., Dudas J., Sebestyen A., Kopper L., and Kovalszky I. Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. Semin. Cancer Biol. 12 (2002) 173-186
2. Iozzo R.V. Matrix proteoglycans: from molecular design to cellular function. Ann. Rev. Biochem. 67 (1998) 609-652
3. Yamagata M., and Kimata K. Repression of a malignant cell-substratum adhesion phenotype by inhibiting the production of the anti-adhesive proteoglycan, PG-M/versican. J. Cell Sci. 107 Pt 9 (1994) 2581-2590
4. Yang B.L., Zhang Y., Cao L., and Yang B.B. Cell adhesion and proliferation mediated through the G1 domain of versican. J. Cell. Biochem. 72 (1999) 210-220
5. LeBaron R.G., Zimmermann D.R., and Ruoslahti E. Hyaluronate binding properties of versican. J. Biol. Chem. 267 (1992) 10003-10010
6. Brown L.F., Guidi A.J., Schnitt S.J., Van De Water L., Iruela-Arispe M.L., Yeo T.K., Tognazzi K., and Dvorak H.F. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin. Cancer Res. 5 (1999) 1041-1056
7. Isogai Z., Shinomura T., Yamakawa N., Takeuchi J., Tsuji T., Heinegard D., and Kimata K. 2B1 antigen characteristically expressed on extracellular matrices of human malignant tumors is a large chondroitin sulfate proteoglycan, PG-M/versican. Cancer Res. 56 (1996) 3902-3908
8. Ito Y., Abiko Y., Tanaka Y., Rahemtulla F., and Kaku T. Immunohistochemical localization of large chondroitin sulfate proteoglycan in odontogenic tumor. Med. Electron Microsc. 35 (2002) 173-177
9. Nara Y., Kato Y., Torii Y., Tsuji Y., Nakagaki S., Goto S., Isobe H., Nakashima N., and Takeuchi J. Immunohistochemical localization of extracellular matrix components in human breast tumours with special reference to PG-M/versican. Histochem. J. 29 (1997) 21-30
10. Theocharis A.D. Human colon adenocarcinoma is associated with specific post-translational modifications of versican and decorin. Biochim. Biophys. Acta 1588 (2002) 165-172
11. Theocharis A.D., Vynios D.H., Papageorgakopoulou N., Skandalis S.S., and Theocharis D.A. Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int. J. Biochem. Cell Biol. 35 (2003) 376-390
12. Touab M., Villena J., Barranco C., Arumi-Uria M., and Bassols A. Versican is differentially expressed in human melanoma and may play a role in tumor development. Am. J. Pathol. 160 (2002) 549-557
13. Tsara M.E., Theocharis A.D., and Theocharis D.A. Compositional and structural alterations of proteoglycans in human rectum carcinoma with special reference to versican and decorin. Anticancer Res. 22 (2002) 2893-2898
14. Voutilainen K., Anttila M., Sillanpaa S., Tammi R., Tammi M., Saarikoski S., and Kosma V.M. Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis. Int. J. Cancer 107 (2003) 359-364
15. Ricciardelli C., Brooks J.H., Suwiwat S., Sakko A.J., Mayne K., Raymond W.A., Seshadri R., LeBaron R.G., and Horsfall D.J. Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin. Cancer Res. 8 (2002) 1054-1060
16. Ricciardelli C., Mayne K., Sykes P.J., Raymond W.A., McCaul K., Marshall V.R., and Horsfall D.J. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin. Cancer Res. 4 (1998) 963-971
17. Lemire J.M., Merrilees M.J., Braun K.R., and Wight T.N. Overexpression of the V3 variant of versican alters arterial smooth muscle cell adhesion, migration, and proliferation in vitro. J. Cell. Physiol. 190 (2002) 38-45
18. Miquel-Serra L., Serra M., Hernandez D., Domenzain C., Docampo M.J., Rabanal R.M., de Torres I., Wight T.N., Fabra A., and Bassols A. V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis. Lab. Invest. 86 (2006) 889-901
19. Toole B.P. Developmental role of hyaluronate. Connect. Tissue Res. 10 (1982) 93-100
20. Laurent T.C., and Fraser J.R. Hyaluronan. FASEB J. 6 (1992) 2397-2404
21. Ropponen K., Tammi M., Parkkinen J., Eskelinen M., Tammi R., Lipponen P., Agren U., Alhava E., and Kosma V.M. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res. 58 (1998) 342-347
22. Toole B.P., Wight T.N., and Tammi M.I. Hyaluronan-cell interactions in cancer and vascular disease. J. Biol. Chem. 277 (2002) 4593-4596
23. Knudson W. Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion. Am. J. Pathol. 148 (1996) 1721-1726
24. Syrokou A., Tzanakakis G.N., Hjerpe A., and Karamanos N.K. Proteoglycans in human malignant mesothelioma. Stimulation of their synthesis induced by epidermal, insulin and platelet-derived growth factors involves receptors with tyrosine kinase activity. Biochimie 81 (1999) 733-744
25. Toole B.P. Hyaluronan promotes the malignant phenotype. Glycobiology 12 (2002) 37R-42R
26. Stiller C.A., Stevens M.C., Magnani C., and Corazziari I. Survival of children with soft-tissue sarcoma in Europe since 1978: results from the EUROCARE study. Eur. J. Cancer 37 (2001) 767-774
27. Piepkorn M., Hovingh P., and Linker A. Evidence for independent metabolism and cell surface localization of cell surface localization of cellular proteoglycans and glycosaminoglycan free chains. J. Cell. Physiol. 135 (1988) 189-199
28. Rasheed S., Nelson-Rees W.A., Toth E.M., Arnstein P., and Gardner M.B. Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer 33 (1974) 1027-1033
29. Thurzo V., Popovic M., Matoska J., Blasko M., Grofova M., Lizonova A., and Steno M. Human neoplastic cells in tissue culture: two established cell lines derived from giant cell tumor and fibrosarcoma. Neoplasma 23 (1976) 577-587
30. Nikitovic D., Zafiropoulos A., Katonis P., Tsatsakis A., Theocharis A.D., Karamanos N.K., and Tzanakakis G.N. Transforming growth factor-beta as a key molecule triggering the expression of versican isoforms v0 and v1, hyaluronan synthase-2 and synthesis of hyaluronan in malignant osteosarcoma cells. IUBMB Life 58 (2006) 47-53
31. Anttila M.A., Tammi R.H., Tammi M.I., Syrjanen K.J., Saarikoski S.V., and Kosma V.M. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res. 60 (2000) 150-155
32. Kosunen A., Ropponen K., Kellokoski J., Pukkila M., Virtaniemi J., Valtonen H., Kumpulainen E., Johansson R., Tammi R., Tammi M., Nuutinen J., and Kosma V.M. Reduced expression of hyaluronan is a strong indicator of poor survival in oral squamous cell carcinoma. Oral Oncol. 40 (2004) 257-263
33. Pirinen R., Tammi R., Tammi M., Hirvikoski P., Parkkinen J.J., Johansson R., Bohm J., Hollmen S., and Kosma V.M. Prognostic value of hyaluronan expression in non-small-cell lung cancer: increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int. J. Cancer 95 (2001) 12-17
34. Toole B.P., Biswas C., and Gross J. Hyaluronate and invasiveness of the rabbit V2 carcinoma. Proc. Natl. Acad. Sci. U. S. A. 76 (1979) 6299-6303
35. Turley E.A. Molecular mechanisms of cell motility. Cancer Metastasis Rev. 11 (1992) 1-3
36. Cattaruzza S., Schiappacassi M., Ljungberg-Rose A., Spessotto P., Perissinotto D., Morgelin M., Mucignat M.T., Colombatti A., and Perris R. Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangiogenesis in vitro. J. Biol. Chem. 277 (2002) 47626-47635
37. Paulus W., Baur I., Dours-Zimmermann M.T., and Zimmermann D.R. Differential expression of versican isoforms in brain tumors. J. Neuropathol. Exp. Neurol. 55 (1996) 528-533
38. Saika S., Kono-Saika S., Tanaka T., Yamanaka O., Ohnishi Y., Sato M., Muragaki Y., Ooshima A., Yoo J., Flanders K.C., and Roberts A.B. Smad3 is required for dedifferentiation of retinal pigment epithelium following retinal detachment in mice. Lab. Invest. 84 (2004) 1245-1258
39. Schonherr E., Kinsella M.G., and Wight T.N. Genistein selectively inhibits platelet-derived growth factor-stimulated versican biosynthesis in monkey arterial smooth muscle cells. Arch. Biochem. Biophys. 339 (1997) 353-361
40. Sakko A.J., Ricciardelli C., Mayne K., Suwiwat S., LeBaron R.G., Marshall V.R., Tilley W.D., and Horsfall D.J. Modulation of prostate cancer cell attachment to matrix by versican. Cancer Res. 63 (2003) 4786-4791
41. Cattaruzza S., Schiappacassi M., Kimata K., Colombatti A., and Perris R. The globular domains of PG-M/versican modulate the proliferation-apoptosis equilibrium and invasive capabilities of tumor cells. FASEB J. 18 (2004) 779-781
42. Mukaratirwa S., van Ederen A.M., Gruys E., and Nederbragt H. Versican and hyaluronan expression in canine colonic adenomas and carcinomas: relation to malignancy and depth of tumour invasion. J. Comp. Pathol. 131 (2004) 259-270
43. Fthenou E., Zafiropoulos A., Tsatsakis A., Stathopoulos A., Karamanos N.K., and Tzanakakis G.N. Chondroitin sulfate A chains enhance platelet derived growth factor-mediated signalling in fibrosarcoma cells. Int. J. Biochem. Cell Biol. 38 (2006) 2141-2150
44. Ellis I., Banyard J., and Schor S.L. Differential response of fetal and adult fibroblasts to cytokines: cell migration and hyaluronan synthesis. Development 124 (1997) 1593-1600
45. Evanko S.P., Angello J.C., and Wight T.N. Formation of hyaluronan- and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1004-1013
46. Evanko S.P., Johnson P.Y., Braun K.R., Underhill C.B., Dudhia J., and Wight T.N. Platelet-derived growth factor stimulates the formation of versican-hyaluronan aggregates and pericellular matrix expansion in arterial smooth muscle cells. Arch. Biochem. Biophys. 394 (2001) 29-38
47. Sakko A.J., Ricciardelli C., Mayne K., Tilley W.D., Lebaron R.G., and Horsfall D.J. Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Res. 61 (2001) 926-930
48. Tzanakakis G.N., Hjerpe A., and Karamanos N.K. Proteoglycan synthesis induced by transforming and basic fibroblast growth factors in human malignant mesothelioma is mediated through specific receptors and the tyrosine kinase intracellular pathway. Biochimie 79 (1997) 323-332
49. Tzanakakis G.N., Karamanos N.K., and Hjerpe A. Effects on glycosaminoglycan synthesis in cultured human mesothelioma cells of transforming, epidermal, and fibroblast growth factors and their combinations with platelet-derived growth factor. Exp. Cell Res. 220 (1995) 130-137
50. Wang H.S., Tung W.H., Tang K.T., Wong Y.K., Huang G.J., Wu J.C., Guo Y.J., and Chen C.C. TGF-beta induced hyaluronan synthesis in orbital fibroblasts involves protein kinase C betaII activation in vitro. J. Cell. Biochem. 95 (2005) 256-267
51. Itano N., Sawai T., Atsumi F., Miyaishi O., Taniguchi S., Kannagi R., Hamaguchi M., and Kimata K. Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J. Biol. Chem. 279 (2004) 18679-18687
52. Itano N., Sawai T., Yoshida M., Lenas P., Yamada Y., Imagawa M., Shinomura T., Hamaguchi M., Yoshida Y., Ohnuki Y., Miyauchi S., Spicer A.P., McDonald J.A., and Kimata K. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J. Biol. Chem. 274 (1999) 25085-25092
53. Spicer A.P., and Nguyen T.K. Mammalian hyaluronan synthases: investigation of functional relationships in vivo. Biochem. Soc. Trans. 27 (1999) 109-115
54. Weigel P.H., Hascall V.C., and Tammi M. Hyaluronan synthases. J. Biol. Chem. 272 (1997) 13997-14000
55. Udabage L., Brownlee G.R., Stern R., and Brown T.J. Inhibition of hyaluronan degradation by dextran sulphate facilitates characterisation of hyaluronan synthesis: an in vitro and in vivo study. Glycoconj. J. 20 (2004) 461-471
56. Kosaki R., Watanabe K., and Yamaguchi Y. Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Res. 59 (1999) 1141-1145
57. Itano N., Atsumi F., Sawai T., Yamada Y., Miyaishi O., Senga T., Hamaguchi M., and Kimata K. Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 3609-3614
58. Jacobson A., Rahmanian M., Rubin K., and Heldin P. Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int. J. Cancer 102 (2002) 212-219
59. Li Y., and Heldin P. Hyaluronan production increases the malignant properties of mesothelioma cells. Br. J. Cancer 85 (2001) 600-607
60. Udabage L., Brownlee G.R., Waltham M., Blick T., Walker E.C., Heldin P., Nilsson S.K., Thompson E.W., and Brown T.J. Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res. 65 (2005) 6139-6150
61. Camenisch T.D., Spicer A.P., Brehm-Gibson T., Biesterfeldt J., Augustine M.L., Calabro Jr. A., Kubalak S., Klewer S.E., and McDonald J.A. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J. Clin. Invest. 106 (2000) 349-360
62. Liu N., Gao F., Han Z., Xu X., Underhill C.B., and Zhang L. Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells. Cancer Res. 61 (2001) 5207-5214
63. Itano N., Sawai T., Miyaishi O., and Kimata K. Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells. Cancer Res. 59 (1999) 2499-2504